Who can be receive mAb treatment?
The FDA has approved the REGEN-COV™ (casirivimab/imdevimab) monoclonal antibody treatment for some adults and children with mild to moderate COVID-19. When started early in the disease, treatment with antibodies may help keep people from getting worse. The treatment is not approved for cases that have advanced past the mild to moderate stage, so it’s important to begin treatment as soon as possible.
To qualify for treatment at UMMC, a person must:
•Have tested positive for COVID-19
•Be within 10 days from beginning of symptoms
•Be at least 12 years old and weigh at least 88 pounds
•Have mild to moderate symptoms, such as fever, cough, or shortness of breath
•Be at high risk of getting worse
A person is at high risk if s/he meets any ONE of the following conditions:
•Age 65 or older
•Body mass index (BMI) greater than or equal to 25; or BMI greater than or equal to the 85th percentile for their age and gender based on CDC growth charts ◦CDC BMI calculator for ages 12 through 19
◦CDC BMI calculator ages 20 and older
•Chronic kidney disease
•Cardiovascular disease/hypertension (including congenital heart disease)
•Chronic lung disease (COPD, moderate to severe asthma, interstitial lung disease, cystic fibrosis, pulmonary hypertension)
•Any of the following immunosuppressive diseases/conditions: ◦AIDS or CD4 count <200 ◦Complement deficiency ◦Grafts-Vs-Host disease (GVHD) ◦HIV infection ◦Immunoglobulin deficiency/ Immunodeficiency ◦Immunosuppressive therapy (within the last 12 months) ◦Leukemia ◦Lymphoma (Hodgkin’s/ Non-Hodgkin’s (NHL)) ◦Metastatic cancer ◦Multiple Myeloma ◦Solid organ malignancy ◦Steroid therapy (within past two weeks) ◦Bone marrow transplant (BMT) or peripheral stem cell transplant (PSCT) ◦Solid organ transplant •Currently receiving immunosuppressive treatment (chemotherapy, transplant immunosuppressants, immune modulators such as Rituximab, etc.) •Sickle cell disease •Neurodevelopmental disorders or other conditions that create medical complexity •Medical-related technological dependence (tracheostomy, gastrostomy, or PPV not related to COVID-19) What to expect during treatment The antibodies are given in shots or IVs. Treatment does not require admission to the hospital. Your appointment will take up to three hours. This includes preparation for treatment, the treatment itself, and time to observe you after treatment. Register for treatment If you meet clinical requirements for treatment, you can make an appointment online at the link below. You will answer a few short questions to establish your eligibility, and then select an available time slot. Note: Monoclonal antibody treatments should not be used for patients who are hospitalized with COVID-19, require oxygen therapy for COVID-19, or have an increase in baseline oxygen flow rate due to COVID-19.